Cardinal Health stock holds above $230 as fresh Q4 figures and buyback plan support valuation
Published on 08/25/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cardinal Health Inc. (US14149Y1082) stock is trading a little above $230 on August 25, 2026, with investors weighing strong recent earnings, fresh capital return plans, and updated guidance that now targets full-year EPS of up to $12.60.
Per a detailed earnings overview dated August 24, 2026, Cardinal Health reported fourth-quarter fiscal 2026 revenue of $63.67 billion, up 5.8% year on year, and diluted EPS of $2.91, beating consensus estimates of $2.42 by $0.49 and underscoring solid execution in its distribution and medical products businesses. The Q4 2026 comparison overview highlights that this revenue print came in 2.7% below analyst expectations but still marked healthy growth versus the prior-year quarter.
On the capital allocation side, Cardinal Health has paired these results with a multi-billion-dollar shareholder return framework, including a newly authorized $5.00 billion share repurchase program, a regular quarterly dividend of $0.5158 per share, and a $4.00 billion revolving credit facility that underpins liquidity for both operations and buybacks. The capital structure and buyback analysis notes that the $5.00 billion authorization sits alongside the dividend, which equates to a $2.06 annual payout and a yield close to 0.9% at current prices.
Recent trading levels and valuation context
Market data snapshots on August 25, 2026 show Cardinal Health stock opening at $232.13 on the New York Stock Exchange, with intraday quotes indicating a modest gain that leaves the share price just above the $230 mark. A same-day institutional filing summary cites this $232.13 opening level as the latest reference price.
In valuation terms, a cross-sectional fundamentals overview dated August 25, 2026 places Cardinal Health at $235.23 per share, implying a forward price-to-earnings multiple of 18.3 times based on projected earnings of roughly $12.85 per share and situating the stock in the mid-to-high-teens range versus healthcare distribution peers. The valuation and margin profile review adds that the company operates with a trailing 12-month GAAP operating margin of 1%, highlighting how modest margin levels interact with scale to deliver sizeable absolute earnings.
Comparing the current trading band with sell-side expectations, several institutional transaction summaries compiled on August 25, 2026 reference an average analyst target price of $266.56 for Cardinal Health, implying upside of roughly 15% when set against the $232.13 opening quote. A combined earnings and guidance digest notes that management has set fiscal 2027 EPS guidance in a range of $12.400 to $12.600, and that equity research models currently center around an EPS forecast of $12.54 for the current fiscal year, making the forward valuation appear balanced relative to that target range. One detailed guidance summary emphasizes that the company carries a consensus rating described as Moderate Buy alongside this $266.56 average target.
Earnings quality, margins, and shareholder returns
The latest quarterly report paints a detailed picture of earnings quality. In the quarter ended August 11, 2026, Cardinal Health generated revenue of $63.67 billion, compared with analyst expectations of $65.15 billion, with the 5.8% year-over-year increase offset by a modest shortfall relative to consensus top-line estimates. Within this framework, diluted EPS of $2.91 exceeded the $2.42 consensus by $0.49, and improved from $2.08 in the same quarter a year earlier, indicating 39.9% growth in per-share earnings despite the slight revenue miss. A comprehensive earnings metrics recap highlights that Cardinal Health posted a net margin of 0.67% during the period and that its revenue trajectory continues to trend upward.
For investors, the combination of narrow margins and large revenue scale is central to the investment case. With a trailing GAAP operating margin of 1% and net margin of 0.67% referenced in recent analyses, small shifts in pricing, mix, or operating efficiency can have outsized effects on EPS, particularly when the company is returning capital via buybacks. The newly authorized $5.00 billion share repurchase plan, layered on top of a regular quarterly dividend of $0.5158 per share, signals management confidence in the cash-generation ability of the business and provides a mechanism to align per-share metrics with overall strategic goals. The buyback scale analysis underscores that this authorization is meaningful relative to the companys current market capitalization.
Looking across the fiscal year, a comparative sector review dated August 24, 2026 states that Cardinal Healths fiscal 2026 performance was characterized as a standout year by its chief executive officer, citing the strong fourth-quarter results, revenue growth, and EPS beat relative to full-year guidance estimates. In the same commentary, the stock was noted as having declined 3.4% since the earnings release and trading at $229 at that time, which contrasts with the subsequent rebound toward the $232 to $235 band by August 25, 2026. The post-earnings performance comparison frames this share-price path in the context of broader healthcare providers and services stocks.
Technical backdrop and institutional interest
Technical commentary published on August 25, 2026 describes a constructive setup for Cardinal Health shares, noting that the stock closed the prior trading session on August 24, 2026 with a gain of 1.25% and that the current quote of 232.4 USD sits within a range viewed as favorable for buyers who are positioning for potential short-term gains. This analysis refers to a stop-loss level set at 55.32 USD as part of a specific trading strategy, using the recent upward momentum as a basis for a bullish interpretation of the trend. A bullish technical reading positions Cardinal Health among the stronger names in the S&P 500 healthcare distribution space based on its recent relative performance.
On the ownership side, multiple filings dated August 25, 2026 indicate that institutional investors have been adding exposure to Cardinal Health. New and expanded positions reported by several asset managers collectively involve stakes measured in tens or hundreds of thousands of shares, providing incremental support to the shareholder base. For instance, filings summarizing investments in Cardinal Health reference individual positions valued in the range of $5.67 million to $9.43 million, reflecting ongoing confidence among professional investors who appear comfortable with the current valuation and earnings trajectory. One such institutional position report combines ownership data with earnings metrics and guidance commentary.
Analyst sentiment captured in these same filings and overviews coalesces around a consensus rating described as Moderate Buy, supported by an average target price of $266.56. When contrasted with the opening quote of $232.13 on August 25, 2026, this target implies prospective upside of roughly 34.43 dollars per share, or close to 15% potential appreciation, contingent on the company meeting its guidance of $12.400 to $12.600 EPS for fiscal 2027. The consensus rating and target-price summary notes that equities research analysts currently expect Cardinal Health to deliver 12.54 EPS for the current fiscal year, aligning tightly with managements guidance midpoint.
Cardinal Healths core distribution and medical products
Beyond the numbers, Cardinal Healths business model remains defined by its role as a critical link in the healthcare supply chain. The company distributes pharmaceuticals and manufactures medical products for hospitals, pharmacies, and other healthcare providers, leveraging decades of experience since its founding as a distribution specialist. A recent overview of profitable healthcare stocks describes Cardinal Health as a global healthcare supply chain participant, emphasizing the breadth of its customer base and the operational scale required to maintain service levels.
Within its medical segment, Cardinal Health markets a wide range of items, including surgical gloves, gowns, drapes, and procedural kits designed to support infection control and clinical efficiency. These products are typically sold under the Cardinal Health brand and are used across operating rooms, outpatient clinics, and other care settings where consistent quality and reliable logistics are essential. As healthcare systems continue to focus on cost containment and resilience, the companys ability to offer integrated distribution and proprietary products provides an important differentiator relative to pure distributors or niche manufacturers.
Stock snapshot and investor takeaway
As of the New York session on August 25, 2026, Cardinal Health stock is trading in the vicinity of $232 to $235 per share, with an evidenced opening quote of $232.13 and a recent reference price of $233.49 reported by market-data providers, indicating a modest gain of 0.48% during early trading. A consolidated news and quote feed lists $233.49 as a fair market value price as of 9:45 a.m. Eastern on August 25, 2026.
For investors, the key numerical anchors are clear: fourth-quarter fiscal 2026 revenue of $63.67 billion, EPS of $2.91 versus $2.42 consensus, and fiscal 2027 EPS guidance of $12.400 to $12.600 frame the fundamental story; a share price in the low $230s and a forward P/E multiple of 18.3 times define the current valuation; and a newly authorized $5.00 billion buyback alongside a $2.06 annual dividend provides a visible capital-return path. Together, these figures suggest that Cardinal Health stock is presently supported by a combination of earnings momentum, shareholder-friendly policies, and institutional interest, even as investors continue to monitor margin dynamics and execution across its large-scale healthcare distribution and medical products operations.
Go deeper
Read more on Cardinal Healths latest earnings presentation, capital allocation strategy, and guidance on the companys investor relations site, including details on segment performance and long-term financial objectives.
Fact box
Company: Cardinal Health Inc.
ISIN: US14149Y1082
Ticker: CAH
Exchange: NYSE
Price (as of August 25, 2026, 9:45 a.m. ET): $233.49 USD
Market cap: $ approximately 42.7 billion (as of August 25, 2026)
Sector / Industry: Health care / Health care providers and services
Index membership: S&P 500
Next earnings date:
